Safety and efficacy of immunotherapy using a double-dose regimen in advanced non-small cell lung cancer (NSCLC): results of IDEE study - Archive ouverte HAL
Article Dans Une Revue Translational Lung Cancer Research Année : 2024

Safety and efficacy of immunotherapy using a double-dose regimen in advanced non-small cell lung cancer (NSCLC): results of IDEE study

Clémence Niel
  • Fonction : Auteur

Résumé

Background: Pembrolizumab 400 mg every six weeks (Q6W) and nivolumab 480 mg every four weeks (Q4W) are used since 2020 and the coronavirus disease 2019 (COVID-19) pandemic. This recommendation relied on pharmacokinetic and pharmacodynamic models. The objective of the IDEE (Immunothérapie Double dose Etendue: Experience bretonne) study is to determine the safety and efficacy of this treatment regimen in real life conditions. Methods: We conducted an observational, retrospective, multicentric study including 117 patients with advanced non-small cell lung cancer (NSCLC) who received pembrolizumab Q6W or nivolumab Q4W between March 2020 and March 2021. Results: The median age was 67 years, 68% were men with predominantly lung adenocarcinoma. The median time to double-dose regimen failure (TDDF) was 9.2 months. The survival rate at 12 months was 79%. TDDF was not influenced by sex, line of treatment, pathologic subtypes or anti-programmed cell death protein 1 (PD-1) antibody. There was no correlation between TDDF and duration of prior exposition to immunotherapy before switching. Sixty-eight patients experienced double-dose treatment failure, 28% because of toxicity including five definitive discontinuations. Five grade ≥3 immune-adverse events were reported included two cases of pneumonitis, all responding to corticosteroid therapy. Conclusions: Our multicentric cohort supports the feasibility of pembrolizumab Q6W and nivolumab Q4W for patients with advanced NSCLC. There is no warning signal regarding safety neither efficacy in our real-life data.
Fichier principal
Vignette du fichier
pdf.html (17.03 Ko) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-04719854 , version 1 (03-10-2024)
hal-04719854 , version 2 (03-10-2024)

Licence

Identifiants

Citer

Clémence Pierre, Yannick Le Guen, Caroline Giordanengo, Thomas Goter, Hervé Léna, et al.. Safety and efficacy of immunotherapy using a double-dose regimen in advanced non-small cell lung cancer (NSCLC): results of IDEE study. Translational Lung Cancer Research, 2024, 13 (8), pp.1807-1815. ⟨10.21037/tlcr-24-141⟩. ⟨hal-04719854v1⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More